CN111902402B - 噁唑化合物晶体 - Google Patents

噁唑化合物晶体

Info

Publication number
CN111902402B
CN111902402B CN201980022064.2A CN201980022064A CN111902402B CN 111902402 B CN111902402 B CN 111902402B CN 201980022064 A CN201980022064 A CN 201980022064A CN 111902402 B CN111902402 B CN 111902402B
Authority
CN
China
Prior art keywords
crystal
infrared absorption
crystals
production method
ointment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980022064.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111902402A (zh
Inventor
金井直彦
安富贵之
广田良辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN111902402A publication Critical patent/CN111902402A/zh
Application granted granted Critical
Publication of CN111902402B publication Critical patent/CN111902402B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980022064.2A 2018-04-04 2019-04-03 噁唑化合物晶体 Active CN111902402B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018072717 2018-04-04
JP2018-072717 2018-04-04
PCT/JP2019/014730 WO2019194211A1 (en) 2018-04-04 2019-04-03 Oxazole compound crystal

Publications (2)

Publication Number Publication Date
CN111902402A CN111902402A (zh) 2020-11-06
CN111902402B true CN111902402B (zh) 2026-07-14

Family

ID=66223774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980022064.2A Active CN111902402B (zh) 2018-04-04 2019-04-03 噁唑化合物晶体

Country Status (26)

Country Link
US (4) US11414391B2 (cg-RX-API-DMAC7.html)
EP (2) EP4400167A3 (cg-RX-API-DMAC7.html)
JP (4) JP7326295B2 (cg-RX-API-DMAC7.html)
KR (2) KR102764726B1 (cg-RX-API-DMAC7.html)
CN (1) CN111902402B (cg-RX-API-DMAC7.html)
AU (2) AU2019249562B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019377A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095866A1 (cg-RX-API-DMAC7.html)
DK (1) DK3774745T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092393A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982586T3 (cg-RX-API-DMAC7.html)
FI (1) FI3774745T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240858T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066793T2 (cg-RX-API-DMAC7.html)
IL (2) IL315425A (cg-RX-API-DMAC7.html)
LT (1) LT3774745T (cg-RX-API-DMAC7.html)
MX (1) MX2020010435A (cg-RX-API-DMAC7.html)
MY (1) MY202406A (cg-RX-API-DMAC7.html)
PH (1) PH12020551605A1 (cg-RX-API-DMAC7.html)
PL (1) PL3774745T3 (cg-RX-API-DMAC7.html)
PT (1) PT3774745T (cg-RX-API-DMAC7.html)
SG (1) SG11202009564TA (cg-RX-API-DMAC7.html)
SI (1) SI3774745T1 (cg-RX-API-DMAC7.html)
TW (2) TWI860993B (cg-RX-API-DMAC7.html)
WO (1) WO2019194211A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006134B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu
EP4501324A4 (en) 2022-03-25 2026-04-08 Otsuka Pharma Co Ltd WOUND TREATMENT COMPOSITION
CN115887463A (zh) * 2022-12-27 2023-04-04 瑞石生物医药有限公司 一种含环酰胺化合物的药物组合物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
US20260076788A1 (en) * 2024-09-17 2026-03-19 Natalie DeVoir Orthodontic composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017115780A1 (en) * 2015-12-28 2017-07-06 Otsuka Pharmaceutical Co., Ltd. Ointment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330639B (en) * 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
EP2890686B1 (en) * 2012-08-30 2017-01-04 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017115780A1 (en) * 2015-12-28 2017-07-06 Otsuka Pharmaceutical Co., Ltd. Ointment

Also Published As

Publication number Publication date
AU2019249562B2 (en) 2024-06-27
AU2024220015A1 (en) 2024-10-17
MX2020010435A (es) 2020-10-28
CA3095866A1 (en) 2019-10-10
IL277730B1 (en) 2024-10-01
IL315425A (en) 2024-11-01
JP2024001115A (ja) 2024-01-09
WO2019194211A1 (en) 2019-10-10
TW202012380A (zh) 2020-04-01
EP4400167A2 (en) 2024-07-17
US20250250243A1 (en) 2025-08-07
EP3774745B1 (en) 2024-05-29
EP3774745A1 (en) 2021-02-17
ZA202006134B (en) 2023-03-29
IL277730B2 (en) 2025-02-01
AU2019249562A1 (en) 2020-10-22
KR20250022254A (ko) 2025-02-14
US20210147370A1 (en) 2021-05-20
JP2021517111A (ja) 2021-07-15
PH12020551605A1 (en) 2021-04-26
TW202515853A (zh) 2025-04-16
JP7326295B2 (ja) 2023-08-15
LT3774745T (lt) 2024-07-10
CN111902402A (zh) 2020-11-06
JP2025128238A (ja) 2025-09-02
SI3774745T1 (sl) 2024-08-30
US20240076275A1 (en) 2024-03-07
IL277730A (en) 2020-11-30
JP2022037040A (ja) 2022-03-08
BR112020019377A2 (pt) 2021-01-05
SG11202009564TA (en) 2020-10-29
HRP20240858T1 (hr) 2024-10-11
FI3774745T3 (fi) 2024-06-19
PL3774745T3 (pl) 2024-08-19
ES2982586T3 (es) 2024-10-16
US11840512B2 (en) 2023-12-12
EP4400167A3 (en) 2024-09-25
US20220411386A1 (en) 2022-12-29
PT3774745T (pt) 2024-06-25
HUE066793T2 (hu) 2024-09-28
EA202092393A1 (ru) 2021-01-25
TWI860993B (zh) 2024-11-11
US11414391B2 (en) 2022-08-16
MY202406A (en) 2024-04-27
KR102764726B1 (ko) 2025-02-11
AU2024220015B2 (en) 2026-03-26
DK3774745T3 (da) 2024-06-17
KR20200139736A (ko) 2020-12-14

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040843

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant